


ERACAL AIMS TO RAISE CHF 15M SERIES A IN 2021: THE ADVISOR

Posted on 12 May 2020



Category: [Rumors](#)

Tags: [EraCal](#), [News](#), [Vischer](#)



EraCal, a Swiss biotech developing an anti-obesity drug, aims to raise CHF 15m in a Series A round next year, [according to Mergermarket](#) who spoke with its CEO. The funds will help the company conduct GLP toxicology and Phase I studies of its lead anti-obesity asset, ERA-107. The Zurich-based company will open the round in 1Q 2021 and aims to close it by summer 2021. To notice that the company closed a CHF 6m seed round in October, with investors including **Redalpine**, **Bernina BioInvest** and the UZH **Life Sciences Fund**, a partnership between UZH Foundation and **Novartis Venture Fund**.

VISCHER is advising EraCal in this operation.